These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
220 related articles for article (PubMed ID: 22723116)
61. [Cilostazol is effective and safe option for the treatment of intermittent claudication. Results of the NOCLAUD study]. Farkas K; Járai Z; Kolossváry E Orv Hetil; 2017 Jan; 158(4):123-128. PubMed ID: 28116935 [TBL] [Abstract][Full Text] [Related]
62. The role of cilostazol in the treatment of intermittent claudication. Barnett AH; Bradbury AW; Brittenden J; Crichton B; Donnelly R; Homer-Vanniasinkam S; Mikhailidis DP; Stansby G Curr Med Res Opin; 2004 Oct; 20(10):1661-70. PubMed ID: 15462700 [TBL] [Abstract][Full Text] [Related]
63. Exercise and peripheral arterial disease. Kim DH Ann Intern Med; 2006 May; 144(9):699; author reply 699-700. PubMed ID: 16670144 [No Abstract] [Full Text] [Related]
64. [Cilostazol improves the quality of life and lower-limb functional capacity also in diabetic patients]. Farkas K; Kolossváry E; Járai Z Orv Hetil; 2020 Sep; 161(38):1637-1645. PubMed ID: 32924968 [TBL] [Abstract][Full Text] [Related]
65. Effect of cilostazol prescribed in a pragmatic treatment program for intermittent claudication. Lee C; Nelson PR Vasc Endovascular Surg; 2014 Apr; 48(3):224-9. PubMed ID: 24399131 [TBL] [Abstract][Full Text] [Related]
66. Studies on the effectiveness and safety of cilostazol, beraprost sodium, prostaglandin E1 for the treatment of intermittent claudication. Hashiguchi M; Ohno K; Saito R Yakugaku Zasshi; 2004 Jun; 124(6):321-32. PubMed ID: 15170067 [TBL] [Abstract][Full Text] [Related]
67. Long-term safety of cilostazol in patients with peripheral artery disease: the CASTLE study (Cilostazol: A Study in Long-term Effects). Hiatt WR; Money SR; Brass EP J Vasc Surg; 2008 Feb; 47(2):330-336. PubMed ID: 18155871 [TBL] [Abstract][Full Text] [Related]
68. Three-curve rocker-soled shoes and gait adaptations to intermittent claudication pain: A randomised crossover trial. Jordan AR; Tew GA; Hutchins SW; Shalan A; Cook L; Thompson A Gait Posture; 2019 Jan; 67():31-36. PubMed ID: 30265963 [TBL] [Abstract][Full Text] [Related]
69. Systematic review the efficacy and safety of cilostazol, pentoxifylline, beraprost in the treatment of intermittent claudication: A network meta-analysis. Liang X; Wang Y; Zhao C; Cao Y PLoS One; 2022; 17(11):e0275392. PubMed ID: 36318524 [TBL] [Abstract][Full Text] [Related]
70. L-Carnitine plus cilostazol versus cilostazol alone for the treatment of claudication in patients with peripheral artery disease: a multicenter, randomized, double-blind, placebo-controlled trial. Goldenberg NA; Krantz MJ; Hiatt WR Vasc Med; 2012 Jun; 17(3):145-54. PubMed ID: 22615190 [TBL] [Abstract][Full Text] [Related]
74. Effects of cilostazol on lipid and fatty acid metabolism. Nakamura N; Osawa H; Yamabe H; Okumura K; Hamazaki T Clin Exp Med; 2005 Mar; 4(4):170-3. PubMed ID: 15750763 [TBL] [Abstract][Full Text] [Related]
75. A phase II dose-ranging study of the phosphodiesterase inhibitor K-134 in patients with peripheral artery disease and claudication. Brass EP; Cooper LT; Morgan RE; Hiatt WR J Vasc Surg; 2012 Feb; 55(2):381-389.e1. PubMed ID: 22119244 [TBL] [Abstract][Full Text] [Related]
76. [Prospects of clinical application of cilostazol for peripheral artery disease]. Burleva EP; Korelin SV Angiol Sosud Khir; 2020; 26(3):28-36. PubMed ID: 33063749 [TBL] [Abstract][Full Text] [Related]